18hon MSN
While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...
Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...
At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
CDC officials say medical professionals are seeing more patients whose illness cannot be traced back to an infected animal or ...
6hon MSN
We recently compiled a list of the Jim Cramer Recently Discussed These 17 Stocks And Chinese Hackers. In this article, we are ...
The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback